Serum Levels of Soluble Syndecan-1 in Hodgkin's Lymphoma

Abstract

Background: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL. Patients and Methods: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals. Results: The levels of syndecan-1 were higher in HL patients than controls (100.2±35.9 ng/ml vs. 67.9±24.5 ng/ml, p<0.001). They marginally correlated with advanced age (p=0.06), male gender (p=0.07) and consequently high IPS (p=0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70±9% vs. 50±11% (p=0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml. Conclusion: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.